Record-breaking support for infectious disease and vaccine development
INFECTIOUS DISEASE EXPERTISE FOR A NEW ERA
20x faster
Patient enrollment rate compared to competing sites for global COVID-19 trials
1,000+
Enrolled patients in infectious disease studies
30M+
Data points captured within two months of activity
Leveraging more than 20 years of experience in clinical trials, Elixia worked with agility to provide robust development support for COVID-19 programs.
We’ve since extended therapeutic coverage to other infectious-disease related studies. It’s a new era in this area of clinical development.
Elixia was well-positioned with relevant capabilities to respond to the growing global need for pharmaceutical partners to develop COVID-19 treatment trials. Elixia played an integral role in achieving global recruitment target goals with world-record speed in the midst of the pandemic.
WE ARE PROUD TO HAVE PARTNERED WITH
Our research areas
Elixia’s research sites and physician investigators have successfully completed studies in many therapeutic subcategories in the infectious disease space.